Ziopharm Oncology Inc. (ZIOP) Stake Held by State Board of Administration of Florida Retirement System
State Board of Administration of Florida Retirement System held its position in Ziopharm Oncology Inc. (NASDAQ:ZIOP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,587 shares of the biotechnology company’s stock at the end of the second quarter. State Board of Administration of Florida Retirement System’s holdings in Ziopharm Oncology were worth $344,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its stake in Ziopharm Oncology by 6.4% in the first quarter. Royal Bank of Canada now owns 16,189 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 974 shares during the period. Fox Run Management L.L.C. purchased a new stake in Ziopharm Oncology during the second quarter worth $133,000. Pacad Investment Ltd. purchased a new stake in Ziopharm Oncology during the first quarter worth $138,000. National Planning Corp raised its stake in Ziopharm Oncology by 23.7% in the first quarter. National Planning Corp now owns 23,969 shares of the biotechnology company’s stock worth $168,000 after buying an additional 4,600 shares during the period. Finally, Creative Planning raised its stake in Ziopharm Oncology by 185.1% in the second quarter. Creative Planning now owns 30,864 shares of the biotechnology company’s stock worth $169,000 after buying an additional 20,040 shares during the period. Hedge funds and other institutional investors own 44.94% of the company’s stock.
Ziopharm Oncology Inc. (NASDAQ:ZIOP) traded down 0.74% during trading on Wednesday, reaching $5.38. 436,650 shares of the company’s stock were exchanged. Ziopharm Oncology Inc. has a 12-month low of $4.45 and a 12-month high of $14.93. The stock’s 50-day moving average is $5.45 and its 200-day moving average is $6.30. The company’s market cap is $702.07 million.
Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. The business earned $1.70 million during the quarter, compared to analysts’ expectations of $1.52 million. Ziopharm Oncology had a negative return on equity of 100.01% and a negative net margin of 2,292.26%. The business’s quarterly revenue was up 525.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.11) EPS. Analysts predict that Ziopharm Oncology Inc. will post ($1.34) EPS for the current fiscal year.
A number of research firms recently weighed in on ZIOP. Mizuho reaffirmed a “neutral” rating and set a $5.00 target price (down previously from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Wells Fargo & Co. raised shares of Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Griffin Securities reaffirmed a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a report on Friday, July 1st. Finally, Zacks Investment Research lowered shares of Ziopharm Oncology from a “buy” rating to a “hold” rating in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $9.75.
About Ziopharm Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ziopharm Oncology Inc. (NASDAQ:ZIOP).
Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.